- Erenumab is a monoclonal antibody targeting CGRP receptor.
- The trial enrolled 81 adults with chronic cluster headache.
- No significant difference in weekly attack reduction compared to placebo.
- 31.7% achieved a 50% reduction in attacks with erenumab.
- 66% of erenumab participants reported adverse events.
- Trial terminated early due to recruitment difficulties.
- Suggests CGRP therapies may be less effective for chronic cluster headaches.
Source: JAMA Network
